Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR445419 in Relapsed or Refractory Acute Myeloid Leukemia
NCT05712278Phase 1Terminated
- Sponsor
- Sanofi
- Start
- Jun 2023
- Primary completion
- Feb 2024
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mbIL21-expanded natural killer cells in acute myeloid leukemia (AML), sponsored by Sanofi. Primary endpoints: Incidence of dose-limiting toxicity at 28 days and Incidence of DLT from start of chemotherapy at 34 days. Started Jun 2023; status: terminated.
02
Drugs
mbIL21-expanded natural killer cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05712278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05712278.